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The Liberia Men’s Health Screening Program for Ebola virus: 
win-win-win for survivor, scientist, and public health 
Among the most important ﬁ ndings to have emerged 
from the massive 2013–16 outbreak of Ebola virus 
disease in west Africa is the delayed clearance of virus 
from the semen of men who survived the disease1–4 and 
the consequent risk of sexual transmission of the virus, 
although this seems to be rare.5 In The Lancet Global Health, 
Moses J Soka and colleagues6 used data from the largest 
cohort (n=466) of male survivors reported so far from 
the Men’s Health Screening Program in Liberia to further 
expand our understanding of this important issue. They 
found that of 38 participants with at least one semen 
specimen that tested positive for Ebola virus, 24 (63%) 
tested positive 12 months or longer after recovery from 
Ebola virus disease, and the longest interval between 
disease recovery and collection of a positive semen 
sample was 565 days. These ﬁ ndings essentially conﬁ rm 
those of previous reports,1–4 but extend the duration that 
Ebola virus RNA can be detected in the semen. 
Although concerning with regard to risk of sexual 
transmission during recovery from Ebola virus disease, 
the results must be interpreted with caution since, as 
with most other studies of Ebola virus persistence, 
conﬁ rmatory virus isolation on cell culture was not done. 
This technique requires access to a biosafety level four 
laboratory, of which none exist in west Africa, and the 
logistical and regulatory obstacles of shipping samples 
internationally to suitable laboratories are formidable. 
Without conﬁ rmatory cell culture, we cannot know 
whether a positive RT-PCR result suggests the presence 
of infectious virus or just residual viral RNA of no concern 
for transmission. In the absence of cell culture data, 
RT-PCR cycle threshold, which is inversely associated 
with viral load, is often used to infer infectivity, although 
standards to reliably and consistently interpret these 
data across laboratories and sample types have not been 
established.7 Only Uyeki and colleagues,2 in their study of 
ﬁ ve male Ebola virus disease survivors in the USA, were 
able to undertake cell culture on the semen samples, with 
the result being that, despite positive RT-PCR results in 
one man over 9 months after acute disease, all culture 
samples that tested positive were taken within 70 days 
and had cycle threshold values of 30 or less. Soka and 
colleagues’ ﬁ ndings in Liberia6 show that almost all mean 
cycle threshold values of men who tested positive for 
Ebola virus on RT-PCR were at least 36 after 3 months, 
suggesting that these men harbour only a small amount 
of infectious virus. Nevertheless, a documented case of 
sexual transmission in Liberia 6 months after acute Ebola 
virus disease,5 along with accumulating evidence of similar 
events,8 remind us that even low levels of virus can result 
in transmission. Until more data are available to clarify 
the risk, Ebola virus disease survivors should continue to 
follow WHO recommendations9 to remain abstinent or 
use condoms until RT-PCR semen testing, beginning at 
3 months after disease onset, is repeatedly negative.
Many questions remain. To assess the relationship 
between RT-PCR results, infectivity, and risk of 
transmission we need to understand the mechanism 
of virus persistence. Persistent RT-PCR positivity, albeit 
at high cycle threshold values, would seem to imply 
ongoing viral replication, particularly for this RNA virus 
without any known mechanism for genome integration 
or latency. Findings from full genome sequencing of 
viruses related to transmission events suggests a reduced 
viral evolutionary rate in the setting of persistence,8 
perhaps related to very-low-level viral replication. 
However, in what cellular compartment in the testis or 
other immune-privileged sites this occurs is unknown. 
Importantly, Soka and colleagues6 provide the ﬁ rst 
suggestion so far of a host determinant of semen 
persistence, with men older than 40 years more likely 
than those aged 40 years or younger to have a positive 
RT-PCR after the ﬁ rst 3 months of recovery (p=0·0004). 
Although age might be a proxy for other risk factors, 
age-related changes in immune function or in semen 
composition could plausibly underlie this ﬁ nding. Are 
there other risk factors that can help identify survivors 
at high risk for virus persistence, thus helping to target 
surveillance activities, while avoiding enhancing the 
stigma they so often encounter? High viraemia during 
acute infection has been postulated to result in deep 
seeding of the immunologically protected sites and delay 
virus clearance,10 as have HIV and other co-infections 
and immunosuppressive disorders, although these 
remain to be deﬁ nitively shown. Unfortunately, Soka and 
colleagues6 did not have access to nadir cycle threshold 
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values or data on illness severity of acute Ebola virus 
disease to explore relationships between these factors 
and semen persistence. Another important question is 
whether experimental antiviral drugs shown to have 
activity against Ebola virus, such as favipiravir11 and 
Gilead-5734,12 can accelerate Ebola virus clearance from 
the semen and other immunologically protected sites. 
Studies are in their early phases.
Equally important to the scientiﬁ c ﬁ ndings of Soka 
and colleagues’ report6 is the context of the activities—
established not as a research study but as a national 
programme oriented toward health service provision 
and risk reduction. The programme packaged semen 
testing with counselling for survivors to promote 
safer sex practices, including condom provision and 
instruction, and enabled referral for other health 
problems that survivors might encounter. A mobile 
team was established to expand programme access and 
to provide counselling for sexual partners. Although 
interpretation of the self-reported results and the 
potential for social desirability bias should be done with 
caution, the public health eﬀ ects of the programme 
seemed to be substantial; participants reported increases 
in abstinence (p<0·0001) and condom use (p<0·0001), 
with 75% feeling “very conﬁ dent” in correct condom use 
at programme graduation. These behavioural changes 
might have not only prevented sexual transmission of 
Ebola virus and potential re-ignition of the outbreak, but 
also other sexually transmitted diseases and unwanted 
pregnancies. 290 (97%) of 299 programme graduates 
reported that they would refer others to participate and 
257 (86%) shared or planned to share their test results 
with their sexual partners. Soka and colleagues6 have 
graciously provided programmatic details in an online 
appendix to facilitate rapid establishment of similar 
programmes elsewhere.
Throughout the Ebola virus disease outbreak in west 
Africa, tension has existed between Ebola virus disease 
survivors as patients (ie, in need of clinical attention), 
as research participants (ie, in need of scientiﬁ c 
attention), and as potential viral reservoirs (ie, in need 
of public health attention), each role requiring a portion 
of the scarce resources for care provision, scientiﬁ c 
investigation, and public health. Although meaningful, 
these divisions are of course false—all three roles are 
important, and must ideally be integrated as much as 
possible into existing routine health services, helping to 
streamline logistics and control costs. The Liberia Men’s 
Health Screening Program represents important progress 
toward addressing these challenges in an integrated 
fashion, and will have broad importance and provides 
opportunity for strengthening health systems that must 
suﬃ  ciently attend to all three needs. We hope that this 
win–win–win approach becomes the norm.
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